Skip to main content
Print Save

Generic Definity RT Availability

Last updated on Nov 7, 2023.

See also: Generic Definity

Definity RT is a brand name of perflutren, approved by the FDA in the following formulation(s):

DEFINITY RT (perflutren - injectable;intravenous)

  • Manufacturer: LANTHEUS MEDCL
    Approval date: November 17, 2020
    Strength(s): 6.52MG/ML [RLD]

Has a generic version of Definity RT been approved?

No. There is currently no therapeutically equivalent version of Definity RT available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity RT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Lipid-encapsulated gas microsphere compositions and related methods
    Patent 10,022,460
    Issued: July 17, 2018
    Inventor(s): Robinson Simon P. & Siegler Robert W. & Onthank David C. & Nguyen Nhung Tuyet
    Assignee(s): Lantheus Medical Imaging, Inc.

    The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.

    Patent expiration dates:

    • December 28, 2035
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Lipid-encapsulated gas microsphere compositions and related methods
    Patent 10,583,207
    Issued: March 10, 2020
    Inventor(s): Robinson Simon P. & Siegler Robert W. & Onthank David C. & Nguyen Nhung Tuyet
    Assignee(s): Lantheus Medical Imaging, Inc.

    The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.

    Patent expiration dates:

    • December 28, 2035
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Methods for making ultrasound contrast agents
    Patent 10,583,208
    Issued: March 10, 2020
    Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
    Assignee(s): Lantheus Medical Imaging, Inc.

    Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Methods and devices for preparation of ultrasound contrast agents
    Patent 10,588,988
    Issued: March 17, 2020
    Inventor(s): Robinson Simon P. & Walker Carol & Onthank David C. & Lazewatsky Joel & Nguyen Nhung Tuyet
    Assignee(s): Lantheus Medical Imaging, Inc.

    Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.

    Patent expiration dates:

    • May 4, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Methods for making ultrasound contrast agents
    Patent 11,266,750
    Issued: March 8, 2022
    Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
    Assignee(s): Lantheus Medical Imaging, Inc.

    Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Patent 11,395,856
    Issued: November 30, -0001

    Patent expiration dates:

    • December 28, 2035
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 11,529,431
    Issued: November 30, -0001

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  • Methods for making ultrasound contrast agents
    Patent 9,789,210
    Issued: October 17, 2017
    Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
    Assignee(s): Lantheus Medical Imaging, Inc.

    Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

    Patent expiration dates:

    • March 16, 2037
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer